Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca Invests In Swedish Venture

by Rick Mullin
April 9, 2012 | A version of this story appeared in Volume 90, Issue 15

AstraZeneca will invest between $5 million and $10 million annually for five years in an academic research institute planned for Sweden. The Science for Life Laboratory, or SciLifeLab, is a joint venture of the Karolinska Institute, the Royal Institute of Technology, Stockholm University, and Uppsala University. To open in 2013, the national institute will investigate the molecular basis of complex human diseases and seek diagnostic biomarkers. In addition to government funding and the AstraZeneca investment, SciLifeLab will get $33 million from the Knut & Alice Wallenberg Foundation, the largest private financer of research in Sweden.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.